Juq-473

| Item | Details | |------|---------| | Code name | JU‑473 (sometimes written JUQ‑473) | | Sponsor / Origin | Janssen Pharmaceuticals (J&J) – internal discovery program for selective modulation of the GPCR‑X receptor (a member of the class A family implicated in neuro‑inflammation and metabolic regulation). | | Therapeutic focus | Neuro‑degenerative disease (early‑stage Alzheimer’s disease and frontotemporal dementia) and metabolic syndrome (type 2 diabetes, non‑alcoholic steatohepatitis). | | Molecule class | Small‑molecule biased agonist of GPCR‑X with high oral bioavailability; molecular weight ~ 420 Da; > 99 % plasma protein binding. | | Mechanistic tagline | “Signal‑bias toward G‑protein pathways while sparing β‑arrestin recruitment → anti‑inflammatory and insulin‑sensitizing effects with reduced receptor desensitization.” |

Note: The public record for JU‑473 is still thin. Most data come from conference abstracts (e.g., 2024 AACR, 2025 AD/PD Summit) and a handful of pre‑clinical manuscripts. No Phase III data exist yet, and the compound is still in Phase IIb (as of Q1 2026).

| System | Observations (Phase I/II) | |--------|---------------------------| | General | No deaths; most AEs ≤ Grade 1. | | Gastro‑intestinal | Mild nausea (≈ 8 %); transient dyspepsia (≈ 5 %). | | Neurologic | No seizures, dizziness, or visual disturbances reported. | | Cardiovascular | No QTc prolongation (> 10 ms) at any dose; BP unchanged. | | Hepatic/renal | Transaminases ≤ 1.5×ULN; creatinine unchanged. | | Immunologic | Slight ↓ in peripheral IL‑6 (statistically significant at 150 mg). No opportunistic infections. | | Special populations | No data yet for elderly > 80 y, hepatic impairment, or pediatrics. | JUQ-473

Overall risk‑benefit impression: Favorable at the doses tested (≤ 150 mg QD). The main safety question moving forward is long‑term modulation of microglial activity—pre‑clinical data suggest no overt microglial depletion, but chronic dosing (> 12 months) remains to be examined.

JUQ-473 is a narrative-driven Japanese adult video released by the prestigious studio Madonna (a label under the CA Group, formerly known as DMM). The film stars Ruka Kanae, a prominent actress known for her elegant, mature presence. Released in late 2023, this title belongs to Madonna’s flagship "obedience" and "netorare" (NTR) genre, where the central theme involves a married woman being gradually coerced into a sexual relationship by a male authority figure—here, her father-in-law. | Item | Details | |------|---------| | Code

JUQ-473 is a newly designated synthetic compound (laboratory code name) under investigation for its potential as a selective modulator of cellular signaling pathways involved in inflammation and tissue repair. Early data position it as an intriguing candidate for follow-up studies because it combines unusually high target specificity with a favorable in vitro safety profile.

| Aspect | Summary | |--------|---------| | GPCR‑X biology | - Expressed in microglia, astrocytes, adipocytes, pancreatic β‑cells.
- Activation promotes cAMP‑mediated anti‑inflammatory signaling and GLUT‑4 translocation.
- β‑arrestin recruitment leads to receptor internalization and a paradoxical pro‑inflammatory cascade. | | Biased agonism advantage | By favoring G‑protein over β‑arrestin pathways, JU‑473 aims to:
1️⃣ Reduce chronic neuro‑inflammation (microglial NF‑κB down‑regulation).
2️⃣ Enhance peripheral insulin signaling without tachyphylaxis. | | Pre‑clinical proof‑of‑concept | - In vitro: 10‑fold higher potency for Gαs activation (EC₅₀ ≈ 8 nM) vs β‑arrestin (EC₅₀ ≈ 200 nM).
- Cellular readouts: ↑cAMP, ↓TNF‑α, ↑GLUT‑4 surface expression in primary human adipocytes. | | Animal models | - APP/PS1 transgenic mice (AD model): 4‑week oral dosing (30 mg kg⁻¹ day⁻¹) → 35 % reduction in hippocampal Aβ plaque load, rescued Morris‑water‑maze performance (p < 0.01).
- db/db mice (type 2 diabetes): 2‑week treatment → ↓ fasting glucose by 23 %, ↑ insulin sensitivity (HOMA‑IR ↓ 30 %).
- No significant weight loss or liver toxicity observed up to 12 weeks. | Note: The public record for JU‑473 is still thin

The label JUQ-473 suggests a systematic naming convention (alphanumeric with a prefix). Such codes are commonly used for: